P300 inhibitors have been examined in the context of advanced PCa patients, and a recent orally available p300/CBP bromodomain inhibitor (CCS1477) has been found to decrease AR and MYC signaling in PC tissues [7]. Here, AR is linked to pachyonychia congenita.